Condition: Graft Failure · Sickle Cell Disease · Hemoglobinopathies · Sponsor: Masonic Cancer Center, University of Minnesota
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
This description comes directly from the study's public registry record.
Ashish Gupta, MBBS, MPH · 612-626-2961 · gupta461@umn.edu
Always discuss trial participation with your own doctor first.
| Masonic Cancer Center | Minneapolis, Minnesota, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06872333